Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05646797
Other study ID # 2074-CL-0101
Secondary ID jRCT2031220554
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date February 28, 2023
Est. completion date December 31, 2027

Study information

Verified date April 2024
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

ASP2074 is a potential new treatment for people with certain solid tumors. Before ASP2074 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body. This information will help find a suitable dose and check for potential medical problems from the treatment. People in this study will be adults with metastatic or locally advanced solid tumors. Metastatic means the cancer has spread to other parts of the body. They will have been previously treated with all available standard therapies and they may no longer be benefitting from further treatment. There are 2 main aims of this study. The first is to learn if people with certain solid tumors have any medical problems after receiving different doses of ASP2074. The second is to find a suitable dose of ASP2074 to use in future studies. This study will be in 2 parts. In Part 1, different small groups of people will receive lower or higher doses of ASP2074. Any medical problems will be recorded at each dose. This is done to find suitable doses of ASP2074 to use in Part 2 of the study. The first group will receive the lowest dose of ASP2074. A medical expert panel will check the results from this group and decide if the next group can receive a higher dose of ASP2074. The panel will do this for each group until all groups have taken ASP2074 or until suitable doses have been selected for Part 2. In Part 2, other different small groups of people will receive ASP2074 with the most suitable doses worked out from Part 1. This will help find a more accurate dose of ASP2074 to use in future studies. ASP2074 will be given as an infusion on the first day of each treatment cycle. The people in this study will have treatment cycles until: they have medical problems from the treatment; their cancer gets worse; they start other cancer treatment; they ask to stop treatment; or they do not come back for treatment. People will visit the clinic on certain days during their treatment, with extra visits during the first 2 cycles of treatment. During these visits, the study doctors will check for any medical problems from ASP2074. At some visits, other checks will include a medical examination, laboratory tests and vital signs. Vital signs include temperature, pulse, and blood pressure. Also, blood and urine samples will be taken. Electrocardiograms will be done to check the heart rhythm during the study. Tumor samples will be taken during certain visits before treatment begins, during treatment, and when treatment has finished. People will visit the clinic within 7 days after stopping treatment. The study doctors will check for any medical problems from ASP2074. Other checks will include a medical examination, laboratory tests and vital signs. Then, people may visit the clinic at 30 days after stopping treatment. Thirty and 90 days after the last dose, the study doctors will check for any medical problems from ASP2074. People will have their vital signs checked and have some laboratory tests. After this, people will continue to visit the clinic every 6 weeks. This is to check the condition of their cancer. They will do this until their cancer is worse, they start other cancer treatment, they ask to leave the study, or they do not come back for treatment. Then, the study doctors will call every 12 weeks for up to 1 year or until that person asks to leave the study, the study is stopped, or the person cannot be reached.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 23
Est. completion date December 31, 2027
Est. primary completion date September 30, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participant has locally-advanced (unresectable) or metastatic solid tumor malignancy (no limit to the number of prior treatment regimens) which is confirmed by available pathology records or current biopsy. For dose escalation, the participant must have colorectal, pancreatic, gastric cancer, esophageal or Gastroesophageal junction (GEJ) adenocarcinoma. For the tumor-specific expansion cohorts, the participant must have colorectal adenocarcinoma, esophageal or GEJ adenocarcinoma, or pancreatic adenocarcinoma. - Participant has at least 1 measurable lesion per RECIST v1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. - Participant has progressed or failed to tolerate after receiving all standard approved therapies or is no longer eligible for standard therapy (no limit to the number of prior treatment regimens). - Participant has an Eastern Cooperative Oncology Group (ECOG) Status of 0 or 1. - Participants who have received radiotherapy must have completed this therapy (including stereotactic radiosurgery) at least 2 weeks prior to study intervention administration. - Participant's adverse events (excluding alopecia) from prior therapy have improved to grade 1 or baseline for the participant (e.g., grade 2 hypothyroidism) within 14 days prior to the first dose of study intervention. - Participant has predicted life expectancy >/= 12 weeks. - Participant must meet all of the criteria based on laboratory tests. In case of multiple laboratory data within this period, the most recent data should be used. If a participant has received a recent blood transfusion, the laboratory tests must be obtained >/= 2 weeks after any blood transfusion. - Female participant is not pregnant confirmed by serum pregnancy test and medical evaluation by interview and at least 1 of the following conditions apply: - Not a woman of childbearing potential (WOCBP) - WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 90 days after final study intervention administration. - Female participant must agree not to breastfeed starting at screening and throughout the study period and for 90 days after final study intervention administration. - Female participant must not donate ova starting at first dose of study intervention and throughout the study period and for 90 days after final study intervention administration. - Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 90 days after final study intervention administration. - Male participant must not donate sperm during the treatment period and for 90 days after final study intervention administration. - Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 90 days after final study intervention administration. - Participant agrees not to participate in another interventional study while receiving study treatment in the present study. Exclusion Criteria: - Participant has received other investigational agents or devices concurrently or within 21 days or 5 half-lives, whichever is shorter, prior to first dose of study intervention administration. - Participant has any condition which makes the participant unsuitable for study participation. - Participant has a known or suspected hypersensitivity to ASP2074 or any components of the formulation used. - Participants with squamous cell colorectal carcinoma; gastrointestinal stromal tumor and neuroendocrine carcinomas. - Participant weighs < 40 kg. - Participant requires or has received systemic steroid therapy or any other immunosuppressive therapy within 14 days prior to study intervention administration. Participants using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day prednisone), receiving a single dose of systemic corticosteroids, or receiving systemic corticosteroids as premedication for radiologic imaging contrast use is eligible. - Participant has symptomatic CNS metastases or participant has evidence of unstable CNS metastases even if asymptomatic (e.g., progression on scans). Participants with previously treated CNS metastases are eligible, if they are clinically stable and have no evidence of central nervous system (CNS) progression by imaging for at least 4 weeks prior to start of study treatment and are not requiring immunosuppressive doses of systemic steroids (> 30 mg per day of hydrocortisone or > 10 mg per day of prednisone or equivalent) for longer than 2 weeks. - Participant has an active autoimmune disease. Participants with type 1 diabetes mellitus, endocrinopathies stably maintained on appropriate replacement therapy, or skin disorders (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment are allowed. - Participant was discontinued from prior immunomodulatory therapy due to a grade >/= 3 toxicity that was mechanistically related (e.g., immune related) to the agent. - Participant is known to have HIV infection. However, participants with HIV infection with CD4+ T-cell counts = 350 cells/µL and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the past 6 months are eligible. NOTE: Screening for human immunodeficiency virus (HIV) infection should be conducted per local requirements. - Participant is known to have active hepatitis B (positive hepatitis B surface antigen (HBsAg)) or hepatitis C infection. NOTE: Screening for these infections should be conducted per local requirements. - For participant who is negative for HBsAg, but hepatitis B core antibody (HBcAb) positive, a hepatitis B virus (HBV) DNA test will be performed and if positive the participant will be excluded. - Participant with positive hepatitis C virus (HCV) serology, but negative HCV RNA test results are eligible. - Participant treated for HCV with undetectable viral load results are eligible - Participant has received a live vaccine against infectious diseases within 28 days prior to initiation of study treatment. - Participant with a history of interstitial lung disease (ILD) or non-infectious pneumonitis, or currently has ILD/pneumonitis. - Participant has an infection requiring systemic therapy within 14 days prior to study drug treatment. - Participant has received a prior allogeneic bone marrow or solid organ transplant. - Participant is expected to require another form of antineoplastic therapy while on study treatment. - Participant with a history of the following significant cardiovascular disease will be excluded: - Participant has inadequately controlled hypertension on antihypertensive medications. - Participant has a history of myocardial infarction or unstable angina within 6 months prior to day 1. - Participant has New York Heart Association Class II or greater Congestive heart failure (CHF). - History of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months prior to study treatment. - Participant has significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to study treatment. - Participant has cardiac arrhythmia, complete left bundle branch block, obligate use of a cardiac pacemaker, long QT syndrome or right bundle branch block with left anterior hemiblock (bifascicular block). - Participant has a corrected time from the start of the Q wave to the end of the T wave (QT) interval (single ECG) using Fridericia's formula (QTcF) > 450 msec during screening. A single 12-lead ECG will be performed during screening. - Participant has had psychiatric illness/social situations that would limit compliance with study requirements. - Participant has a prior malignancy, other than the current malignancy for which the participant is seeking treatment, active (i.e., requiring treatment of intervention) within the previous 2 years except for locally curable malignancies that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast. - Participant has had major surgery within 28 days prior to the start of study treatment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ASP2074
intravenous (IV) infusion

Locations

Country Name City State
Japan National Cancer Center Hospital Chuo-ku Tokyo
Japan National Cancer Center Hospital East Kashiwa Chiba
Japan The Cancer Institute Hospital of Japanese Foundation for Cancer Research Koto-ku Tokyo
Japan Aichi Cancer Center Nagoya Aichi
Japan Osaka International Cancer Institute Osaka
United States Karmanos Cancer Institute Detroit Michigan
United States Duke University Durham North Carolina
United States START Midwest Grand Rapids Michigan
United States University of Iowa Hospitals Iowa City Iowa
United States Rhode Island Hospital Providence Rhode Island
United States University of California Davis Health System Sacramento California
United States Next Oncology - Oncology San Antonio Texas
United States Virginia Mason Medical Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Astellas Pharma Global Development, Inc.

Countries where clinical trial is conducted

United States,  Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Dose Limiting Toxicities (DLTs) for ASP2074 A Dose Limiting Toxicity (DLT) is defined as any prespecified Adverse events (AEs) or laboratory findings occurring during the DLT evaluation period excluding toxicities clearly related to disease progression or intercurrent illness. Up to up to 28 Days
Primary Number of participants with Adverse Events (AEs) Adverse events (AEs) will be coded using MedDRA. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Up to 15 Months
Primary Number of participants with Serious Adverse Events (SAEs) A Serious Adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or other medically important event. Up to 15 Months
Primary Number of participants with laboratory value abnormalities and/or adverse events (AEs) Number of participants with potentially clinically significant laboratory values. Up to 13 Months
Primary Number of participants with vital sign abnormalities and/or adverse events (AEs) Number of participants with potentially clinically significant vital sign values. Up to 15 Months
Primary Number of participants with electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs) Number of participants with potentially clinically significant ECG values. Up to 15 Months
Secondary Objective Response Rate (ORR) per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST) ORR is defined as is defined as the proportion of participants whose best overall response is a confirmed Complete Response (CR) or Partial Response (PR). Up to 21 Months
Secondary Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 ORR is defined as the proportion of participants whose best overall response is a confirmed Complete Response (CR) or Partial Response (PR). Up to 21 Months
Secondary Duration of Response (DOR) per iRECIST DOR is defined as the time from the date of first documented response (CR or PR that is subsequently confirmed) to the date of first documented disease progression (PD) or death due to any cause, whichever occurs first. DOR will only be calculated for participants with confirmed CR or PR. Up to 21 Months
Secondary Duration of Response (DOR) per RECIST v1.1 DOR is defined as the time from the date of first documented response (CR or PR that is subsequently confirmed) to the date of first documented PD or death due to any cause, whichever occurs first. DOR will only be calculated for participants with confirmed CR or PR. Up to 21 Months
Secondary Disease Control Rate (DCR) per iRECIST DCR is defined as the proportion of participants whose best overall response is confirmed CR, PR or stable disease (SD). Up to 21 Months
Secondary Disease Control Rate (DCR) per RECIST v1.1 DCR is defined as the proportion of participants whose best overall response is confirmed CR, PR or stable disease (SD). Up to 21 Months
Secondary Change from Baseline in Serum CA19-9 levels in participants with pancreatic cancer Serum carbohydrate antigen 19-9 (CA19-9) levels will be recorded in participants with pancreatic cancer. Baseline and up to 21 Months
Secondary Pharmacokinetics (PK) of ASP2074 in serum: AUC(0-336h) Area under the concentration-time curve from time zero to 336 hours post dose (AUC(0-336h)) will be recorded from the PK serum samples collected. Up to 12 Months
Secondary Pharmacokinetics (PK) of ASP2074 in serum: Cmax Maximum concentration (Cmax) will be recorded from the PK serum samples collected. Up to 12 Months
Secondary Pharmacokinetics (PK) of ASP2074 in serum: Ctrough Concentration immediately prior to dosing at multiple dosing (Ctrough) will be recorded from the PK serum samples collected. Up to 12 Months
Secondary Pharmacokinetics (PK) of ASP2074 in serum: tmax Time of maximum concentration (tmax) will be recorded from the PK serum samples collected. Up to 12 Months
Secondary Change from Baseline in target antigen expression Comparison of target antigen expression in baseline versus on-treatment tumor biopsies will be performed. Baseline and up to Day 40
Secondary Change from Baseline in tumor CD8 infiltration/ activation Comparison of CD8 infiltration/ activation in baseline versus on-treatment tumor biopsies will be performed. Baseline and up to Day 40
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04972981 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT05086822 - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors Phase 1
Completed NCT03260322 - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT06040541 - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Phase 1
Recruiting NCT05862831 - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT03641794 - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers Phase 1
Terminated NCT03665129 - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Recruiting NCT05914116 - A Study of DB-1311 in Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01693562 - A Phase 1/2 Study to Evaluate MEDI4736 Phase 1/Phase 2
Recruiting NCT04387916 - A Study of KC1036 in Patients With Advanced Solid Tumors Phase 1
Completed NCT04095273 - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Phase 1
Not yet recruiting NCT03692520 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02997176 - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Phase 1
Recruiting NCT04446260 - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT02253992 - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT06076291 - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT03545971 - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors. Phase 1